X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (54776) 54776
Newspaper Article (435) 435
Newsletter (340) 340
Magazine Article (117) 117
Book Chapter (92) 92
Book / eBook (73) 73
Government Document (35) 35
Web Resource (27) 27
Dissertation (13) 13
Publication (9) 9
Book Review (4) 4
Conference Proceeding (4) 4
Reference (3) 3
Streaming Video (2) 2
Report (1) 1
Trade Publication Article (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50270) 50270
female (45738) 45738
oncology (24555) 24555
ovarian cancer (19687) 19687
middle aged (18368) 18368
ovarian neoplasms - drug therapy (16729) 16729
adult (16324) 16324
cancer (15298) 15298
ovarian neoplasms - pathology (15087) 15087
aged (13747) 13747
chemotherapy (10650) 10650
animals (8916) 8916
obstetrics & gynecology (8207) 8207
ovarian-cancer (7725) 7725
cell line, tumor (7715) 7715
prognosis (7713) 7713
carcinoma (6838) 6838
ovarian neoplasms - therapy (6643) 6643
tumors (6526) 6526
male (6079) 6079
ovarian neoplasms - genetics (6042) 6042
antineoplastic combined chemotherapy protocols - therapeutic use (6010) 6010
mice (5796) 5796
neoplasm staging (5727) 5727
expression (5638) 5638
research (5579) 5579
ovarian neoplasms - metabolism (5555) 5555
ovarian neoplasms - surgery (5382) 5382
care and treatment (5078) 5078
breast cancer (4946) 4946
treatment outcome (4706) 4706
antineoplastic agents - therapeutic use (4595) 4595
apoptosis (4505) 4505
survival (4503) 4503
health aspects (4390) 4390
breast-cancer (4385) 4385
metastasis (4385) 4385
cisplatin (4334) 4334
aged, 80 and over (4298) 4298
analysis (4144) 4144
ovarian neoplasms - mortality (4118) 4118
surgery (3953) 3953
retrospective studies (3850) 3850
combined modality therapy (3549) 3549
risk factors (3530) 3530
ovarian neoplasms - diagnosis (3522) 3522
antineoplastic agents - pharmacology (3438) 3438
gene expression (3378) 3378
genetic aspects (3286) 3286
paclitaxel (3275) 3275
proteins (3271) 3271
therapy (3252) 3252
adolescent (3145) 3145
cancer therapies (3127) 3127
women (3049) 3049
immunohistochemistry (2931) 2931
hematology, oncology and palliative medicine (2899) 2899
medicine & public health (2871) 2871
mutation (2844) 2844
cisplatin - administration & dosage (2815) 2815
survival rate (2688) 2688
ovarian carcinoma (2644) 2644
diagnosis (2637) 2637
mice, nude (2633) 2633
pharmacology & pharmacy (2607) 2607
gene expression regulation, neoplastic (2580) 2580
drug resistance, neoplasm (2563) 2563
obstetrics and gynecology (2561) 2561
disease-free survival (2556) 2556
tumor cells, cultured (2544) 2544
cell biology (2530) 2530
survival analysis (2463) 2463
follow-up studies (2461) 2461
medicine (2430) 2430
development and progression (2408) 2408
research article (2373) 2373
pathology (2370) 2370
apoptosis - drug effects (2327) 2327
medical prognosis (2311) 2311
neoplasms - drug therapy (2239) 2239
biochemistry & molecular biology (2235) 2235
time factors (2187) 2187
paclitaxel - administration & dosage (2180) 2180
breast neoplasms - drug therapy (2174) 2174
cells (2166) 2166
carcinoma, ovarian epithelial (2153) 2153
oncology, experimental (2130) 2130
young adult (2090) 2090
patients (2079) 2079
breast neoplasms - genetics (2038) 2038
medicine, research & experimental (2009) 2009
risk (1982) 1982
antineoplastic agents - administration & dosage (1968) 1968
antineoplastic combined chemotherapy protocols - adverse effects (1929) 1929
carboplatin (1914) 1914
studies (1896) 1896
cell proliferation (1876) 1876
drug resistance (1863) 1863
dose-response relationship, drug (1860) 1860
cell proliferation - drug effects (1827) 1827
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (28) 28
Online Resources - Online (17) 17
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (9) 9
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Credit Valley Hospital - Online (1) 1
Lakeridge Health Sciences - Online (1) 1
Media Commons - Audio Visual (1) 1
Regis College - Circulation Desk (1) 1
Scarborough Hospital - General (1) 1
St. Michael's College (John M. Kelly) - Audio Visual (1) 1
St. Michael's Hospital - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University Emmanuel College - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (52433) 52433
German (965) 965
Japanese (853) 853
French (716) 716
Chinese (495) 495
Russian (454) 454
Polish (245) 245
Italian (210) 210
Spanish (149) 149
Czech (122) 122
Hungarian (67) 67
Dutch (50) 50
Bulgarian (45) 45
Korean (43) 43
Portuguese (43) 43
Danish (37) 37
Croatian (28) 28
Ukrainian (26) 26
Swedish (25) 25
Hebrew (21) 21
Finnish (19) 19
Norwegian (17) 17
Serbian (14) 14
Romanian (12) 12
Turkish (11) 11
Slovak (6) 6
Arabic (2) 2
Lithuanian (2) 2
Slovenian (2) 2
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CA: a cancer journal for clinicians, ISSN 0007-9235, 2016, Volume 66, Issue 5, pp. 408 - 436
Answer questions and earn CME/CNE In this report, a team of surgical pathologists has provided a review of intraepithelial neoplasia in a host of (but not all)... 
carcinoma in situ | dysplasia | intraepithelial neoplasia | preinvasive neoplasia | precancer | HIGH-GRADE DYSPLASIA | URINARY-BLADDER | BARRETTS-ESOPHAGUS | HUMAN-PAPILLOMAVIRUS | INTRADUCTAL CARCINOMA | CARCINOMA IN-SITU | PAPILLARY UROTHELIAL HYPERPLASIA | ONCOLOGY | SINGLE ACADEMIC CENTER | TERM-FOLLOW-UP | NECK-CANCER IMPLICATIONS | Humans | Lung Neoplasms - metabolism | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Male | Uterine Cervical Neoplasms - pathology | Head and Neck Neoplasms - metabolism | Breast Neoplasms - metabolism | Esophageal Neoplasms - pathology | Breast Neoplasms - therapy | American Cancer Society | Uterine Cervical Neoplasms - metabolism | Skin Neoplasms - diagnosis | Urinary Bladder Neoplasms - pathology | Female | Ovarian Neoplasms - metabolism | Uterine Cervical Neoplasms - therapy | Skin Neoplasms - pathology | Prostatic Neoplasms - pathology | Uterine Cervical Neoplasms - diagnosis | Skin Neoplasms - therapy | Carcinoma in Situ - pathology | Ovarian Neoplasms - diagnosis | Pancreatic Neoplasms - pathology | Risk Factors | Head and Neck Neoplasms - therapy | Lung Neoplasms - therapy | Carcinoma in Situ - therapy | Head and Neck Neoplasms - pathology | Skin Neoplasms - metabolism | Breast Neoplasms - pathology | Ovarian Neoplasms - therapy | Head and Neck Neoplasms - diagnosis | Breast Neoplasms - diagnosis | Carcinoma in Situ - diagnosis | Carcinoma in Situ - metabolism | Lung Neoplasms - diagnosis | Population Surveillance | Prevention | Care and treatment | Gastrointestinal system | Practice | Pathologists | Metastasis | Patients | Health aspects | Cervical cancer | Risk factors | Pathology | Usage | Diagnosis | Tumors | Medical diagnosis | Cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2010, Volume 78, Issue 1, pp. 127 - 135
... (O/E = 0.78; CI, 0.72–0.84), and esophagus (O/E = 0.58; CI, 0.37–0.86) SPMs. Patients receiving external-beam radiotherapy for endometrial... 
Radiology | Hematology, Oncology and Palliative Medicine | Radiation-induced malignancies | HNPCC | Endometrial cancer | Second primary malignancies | SURGERY | LYNCH-SYNDROME | NONPOLYPOSIS COLORECTAL-CANCER | 2ND PRIMARY CANCERS | RISK | CERVICAL-CANCER | RADIATION-THERAPY | UTERINE | ONCOLOGY | OVARIAN | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | United States - epidemiology | Colonic Neoplasms - genetics | Follow-Up Studies | Humans | Middle Aged | Bone Neoplasms - epidemiology | Pharyngeal Neoplasms - etiology | Esophageal Neoplasms - epidemiology | Incidence | Vaginal Neoplasms - genetics | Young Adult | Neoplasms, Radiation-Induced - genetics | Endometrial Neoplasms - genetics | Lung Neoplasms - etiology | Aged, 80 and over | Intestine, Small - radiation effects | Bone Neoplasms - genetics | Neoplasms, Second Primary - genetics | Mouth Neoplasms - genetics | SEER Program | Risk Assessment | Vaginal Neoplasms - etiology | Mouth Neoplasms - etiology | Neoplasms, Second Primary - epidemiology | Mouth Neoplasms - epidemiology | Pharyngeal Neoplasms - genetics | Vaginal Neoplasms - epidemiology | Adolescent | Pharyngeal Neoplasms - epidemiology | Endometrial Neoplasms - radiotherapy | Esophageal Neoplasms - etiology | Age Factors | Neoplasms, Radiation-Induced - etiology | Urinary Bladder Neoplasms - genetics | Adult | Female | Intestinal Neoplasms - genetics | Urinary Bladder Neoplasms - epidemiology | Colonic Neoplasms - etiology | Lung Neoplasms - genetics | Urinary Bladder Neoplasms - etiology | Colonic Neoplasms - epidemiology | Intestinal Neoplasms - etiology | Intestinal Neoplasms - epidemiology | Bone Neoplasms - etiology | Neoplasms, Second Primary - etiology | Lung Neoplasms - epidemiology | Esophageal Neoplasms - genetics | Aged | Neoplasms, Radiation-Induced - epidemiology | Genetic aspects | Research | Oncology, Experimental | Cancer | Index Medicus | LARGE INTESTINE | GASTROINTESTINAL TRACT | ORAL CAVITY | ESOPHAGUS | DIGESTIVE SYSTEM | LUNGS | MEDICINE | PHARYNX | THERAPY | RADIOLOGY AND NUCLEAR MEDICINE | BLADDER | RADIOTHERAPY | RADIOLOGY | SMALL INTESTINE | NEOPLASMS | UTERUS | INTESTINES | NUCLEAR MEDICINE | FEMALE GENITALS | ORGANS | URINARY TRACT | DISEASES | RESPIRATORY SYSTEM | BRACHYTHERAPY | BODY
Journal Article
Nature cell biology, ISSN 1476-4679, 2018, Volume 20, Issue 8, pp. 954 - 965
BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To... 
PATHWAY CHOICE | STRAND BREAK REPAIR | RESECTION | DAMAGE-RESPONSE | 53BP1 | CLASS-SWITCH RECOMBINATION | FANCONI-ANEMIA | DIFFERENTIAL EXPRESSION ANALYSIS | POLYMERASE-ZETA | TELOMERES | CELL BIOLOGY | Osteosarcoma - drug therapy | Mad2 Proteins - metabolism | Humans | Multiprotein Complexes | Ovarian Neoplasms - pathology | Bone Neoplasms - pathology | DNA Breaks, Double-Stranded | Bone Neoplasms - metabolism | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | Telomere-Binding Proteins - genetics | DNA End-Joining Repair | HEK293 Cells | Female | Bone Neoplasms - genetics | Ovarian Neoplasms - metabolism | Bone Neoplasms - drug therapy | BRCA1 Protein - deficiency | Telomere-Binding Proteins - metabolism | Ovarian Neoplasms - drug therapy | Osteosarcoma - metabolism | DNA-Binding Proteins | Tumor Suppressor p53-Binding Protein 1 - metabolism | Recombinational DNA Repair | Tumor Suppressor p53-Binding Protein 1 - genetics | Cisplatin - pharmacology | Breast Neoplasms - drug therapy | Proteins - genetics | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Proteins - metabolism | Breast Neoplasms - pathology | Mad2 Proteins - genetics | Cell Line, Tumor | Mice | Osteosarcoma - genetics | Cell Cycle Proteins | Osteosarcoma - pathology | Care and treatment | DNA | Cancer cells | Breast cancer | Genetic aspects | Research | Gene expression | Single-stranded DNA | DNA damage | Homologous recombination | Poly(ADP-ribose) | Homology | Genomes | Inactivation | Proteins | Ribose | Null cells | Deoxyribonucleic acid--DNA | BRCA2 protein | CRISPR | Deactivation | BRCA1 protein | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Oligosaccharides | Double-strand break repair | Screens | Cisplatin | Inhibitors | Prostate | Viability | Tumors | Telomere-Binding Proteins / metabolism | Osteosarcoma / genetics | Telomere-Binding Proteins / genetics | BRCA1 Protein / genetics | Cellular Biology | Genetics | Proteins / genetics | Osteosarcoma / drug therapy | Ovarian Neoplasms / genetics | Mad2 Proteins / genetics | Proteins / metabolism | Breast Neoplasms / drug therapy | Breast Neoplasms / metabolism | Tumor Suppressor p53-Binding Protein 1 / genetics | BRCA1 Protein / deficiency | Ovarian Neoplasms / metabolism | Mad2 Proteins / metabolism | Breast Neoplasms / pathology | Bone Neoplasms / genetics | Ovarian Neoplasms / pathology | Bone Neoplasms / pathology | Life Sciences | Bone Neoplasms / drug therapy | Ovarian Neoplasms / drug therapy | Osteosarcoma / metabolism | Biochemistry, Molecular Biology | Breast Neoplasms / genetics | Drug Resistance, Neoplasm / genetics | Osteosarcoma / pathology | Bone Neoplasms / metabolism | Poly(ADP-ribose) Polymerase Inhibitors / pharmacology | Cisplatin / pharmacology | Molecular biology | Tumor Suppressor p53-Binding Protein 1 / metabolism | Cancer
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 12/2015, Volume 10, Issue 12, p. e0145754
... clinical response to their primary therapy, nearly half will develop disease recurrence within 18 months and the majority will die from disease recurrence within 5 years... 
CA-125 | MULTIDISCIPLINARY SCIENCES | EPITHELIAL OVARIAN-CANCER | Endometrial Neoplasms - mortality | Humans | Middle Aged | Ovarian Neoplasms - mortality | Genital Neoplasms, Female - drug therapy | DNA, Neoplasm - blood | Endometrial Neoplasms - genetics | Adult | Female | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Genital Neoplasms, Female - genetics | CA-125 Antigen - blood | Ovarian Neoplasms - blood | Genital Neoplasms, Female - blood | Mutation - genetics | Breast Neoplasms - drug therapy | Biomarkers, Tumor - blood | Genital Neoplasms, Female - mortality | Exome - genetics | Breast Neoplasms - genetics | Breast Neoplasms - blood | Breast Neoplasms - mortality | Endometrial Neoplasms - drug therapy | Neoplasm Recurrence, Local - genetics | Aged | Biomarkers, Tumor - genetics | DNA, Neoplasm - genetics | Endometrial Neoplasms - blood | Physiological aspects | Prognosis | Biological markers | Genital cancer | Tumors | Plasma | Scanning | Ovarian carcinoma | Fallopian tube | Cancer therapies | Ovarian cancer | Gene sequencing | Computed tomography | Surgery | Quality | Imaging | Endometrium | Deoxyribonucleic acid--DNA | DNA probes | Gynecology | Breast cancer | Patients | Survival | Obstetrics | Medicine | Lead time | Chemotherapy | Surveillance | Womens health | Biomarkers | Diagnostic systems | Mutation | Reproductive system | Uterine cancer | Peritoneum | Cancer | Deoxyribonucleic acid | DNA
Journal Article
EMBO molecular medicine, ISSN 1757-4684, 2014, Volume 6, Issue 10, pp. 1279 - 1293
Epithelial‐mesenchymal transition (EMT) is a reversible and dynamic process hypothesized to be co‐opted by carcinoma during invasion and metastasis. Yet, there... 
drug response | microarray | gene expression signature | epithelial‐mesenchymal transition | prognosis | Drug response | Epithelial-mesenchymal transition | Prognosis | Microarray | Gene expression signature | MOLECULAR SUBTYPES | MEDICINE, RESEARCH & EXPERIMENTAL | GENE-EXPRESSION SIGNATURE | STEM-CELLS | GENOMIC ANALYSES | OVARIAN-CANCER | NEGATIVE BREAST-CANCER | CLINICAL-RELEVANCE | MICRORNA CONTROL | CLAUDIN-LOW | epithelial-mesenchymal transition | SIGNATURE PREDICTS RESISTANCE | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | Colorectal Neoplasms - genetics | Humans | Epithelial-Mesenchymal Transition - drug effects | Antineoplastic Agents - therapeutic use | Epithelial-Mesenchymal Transition - genetics | Ovarian Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Neoplasms - genetics | Colorectal Neoplasms - drug therapy | Female | Gene Expression Regulation, Neoplastic - drug effects | Ovarian Neoplasms - drug therapy | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | Treatment Outcome | Transcriptome - drug effects | Transcriptome - genetics | Stomach Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Cell Line, Tumor | Cancer patients | Chemotherapy | Patient outcomes | Stem cells | Development and progression | Drug therapy | Gene expression | Ovarian cancer | Cancer | Mesenchyme | Colorectal carcinoma | Genomes | Breast cancer | Metastasis | Kinases | Cancer therapies | Metastases | Breast carcinoma | Genotype & phenotype | Paclitaxel | Breast | Software | Tumors
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
Gynecologic oncology, ISSN 0090-8258, 2013, Volume 131, Issue 1, pp. 36 - 41
Abstract Objective We evaluated the clinical outcome and prognostic factors for post-relapse survival (PRS) in a large retrospective series of ovarian cancer... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Anatomic site of disease | Favourable prognosis | Recurrent ovarian cancer | Localized relapse | Secondary debulking surgery | SURVIVAL | METASTASIS | SECONDARY CYTOREDUCTIVE SURGERY | IDENTIFICATION | CHEMOTHERAPY | OBSTETRICS & GYNECOLOGY | 2ND-LINE | THERAPY | CISPLATIN | ONCOLOGY | RECURRENT | CARCINOMA | Lymph Nodes - pathology | Follow-Up Studies | Lymph Nodes - surgery | Humans | Middle Aged | Brain Neoplasms - pathology | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Brain Neoplasms - surgery | Neoplasm Recurrence, Local - pathology | Platinum Compounds - therapeutic use | Young Adult | Brain Neoplasms - secondary | Lung Neoplasms - secondary | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Retrospective Studies | Liver Neoplasms - secondary | Carcinoma - secondary | Peritoneal Neoplasms - secondary | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Neoplasm Recurrence, Local - therapy | Peritoneal Neoplasms - surgery | Neoplasms, Glandular and Epithelial - therapy | Liver Neoplasms - surgery | Lymphatic Metastasis | Splenic Neoplasms - surgery | Splenic Neoplasms - pathology | Carcinoma, Ovarian Epithelial | Ovarian Neoplasms - therapy | Carcinoma - therapy | Aged | Neoplasm Staging | Splenic Neoplasms - secondary | Care and treatment | Cancer patients | Prognosis | Patient outcomes | Ovarian cancer
Journal Article